Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). METHODS: This 52-week, multicentre,...

Descripción completa

Detalles Bibliográficos
Autores principales: Combe, Bernard, Kivitz, Alan, Tanaka, Yoshiya, van der Heijde, Désirée, Simon, J Abraham, Baraf, Herbert S B, Kumar, Uma, Matzkies, Franziska, Bartok, Beatrix, Ye, Lei, Guo, Ying, Tasset, Chantal, Sundy, John S, Jahreis, Angelika, Genovese, Mark C, Mozaffarian, Neelufar, Landewé, Robert B M, Bae, Sang-Cheol, Keystone, Edward C, Nash, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237199/
https://www.ncbi.nlm.nih.gov/pubmed/33504485
http://dx.doi.org/10.1136/annrheumdis-2020-219214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237199/
https://www.ncbi.nlm.nih.gov/pubmed/33504485
http://dx.doi.org/10.1136/annrheumdis-2020-219214

Ejemplares similares